Swedish Genovis Launches US Operation

Due to demand for its products in the US market, Genovis hired Christopher Wilkins to head its US subsidiary; his responsibilities also include global marketing initiatives.

“I’m delighted that Chris chose Genovis,” says Sarah Fredriksson, CEO of Genovis AB. “Staffing is crucial when an operation like Genovis expands internationally. I’m convinced that Chris will drive the business in the right direction and enable successful global marketing activities.”

Wilkins brings extensive biotech industry experience to the Genovis operation. He has held executive positions in sales, marketing, and business development at Cepheid, Inc. and MJ Research, Inc. (owned by Bio-Rad since 2004). He earned his Ph.D. in Genetics & Biochemistry at Cornell University in Ithaca, New York.

Genovis has also recently launched a new web site that enables online sales. The site’s first customers were in the US, which is the largest single market for Genovis products. Consequently, the company decided to establish Genovis Inc. Going forward, Wilkins will have primary responsibility for global marketing efforts.

“Heading up Genovis Inc. and having responsibility for global marketing is a great challenge,” says Wilkins. “The Genovis proposition includes top-quality products based on innovative technologies that can be utilized in a wide range of research applications. Building the US organization and enabling the company to realize its global potential is very exciting.”

Genovis is currently focusing on two business areas: bimolecular delivery and antibody engineering. Its product portfolio contains NIMT® FeOsilence, NIMT® FeOfection, NIMT® FeOlabeling, and NIMT® FabRICATOR. Further product launches are planned this autumn. While the company’s customers are spread across the entire US, one business-critical region is the Boston area in Massachusetts where Genovis Inc. is located.

Find out more, contact:

Sarah Fredriksson, CEO, Genovis AB

Tel: +46 46 10 12 35


Genovis is a biotechnology company with distinguished core competency in the fields of nanotechnology and nanoparticles. The company’s patented NIMT® technology (NanoInducedMagneticTransfer) has been developed in order to enable the life science industry to conduct effective preclinical research. Genovis shares are listed on the First North stock exchange (OMX). Mangold Fondkommission AB is a Certified Advisor and guarantor of liquidity to the company.